Shares of Extendicare Inc. (TSE:EXE – Get Free Report) have received an average rating of “Buy” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is C$23.86.
A number of analysts recently weighed in on EXE shares. Cibc World Mkts raised shares of Extendicare to a “strong-buy” rating in a report on Monday, September 22nd. TD Securities upped their price target on shares of Extendicare from C$15.00 to C$19.00 in a report on Thursday, November 13th. Canaccord Genuity Group increased their price objective on Extendicare from C$20.00 to C$22.50 in a research report on Thursday, December 4th. Cormark lifted their price objective on Extendicare from C$25.00 to C$30.00 in a research note on Wednesday, December 3rd. Finally, National Bankshares boosted their target price on Extendicare from C$21.50 to C$24.50 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd.
Extendicare Trading Up 2.9%
Extendicare Dividend Announcement
The business also recently disclosed a monthly dividend, which was paid on Monday, November 17th. Investors of record on Monday, November 17th were given a $0.042 dividend. This represents a c) annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Friday, October 31st. Extendicare’s dividend payout ratio is 46.60%.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Further Reading
- Five stocks we like better than Extendicare
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- This stock gets a 94 out of 100
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- How the Rich Retire
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
